The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

IntroductionThe ability to modulate and enhance the anti-tumor immune responses is critical in developing novel therapies in cancer. The Tumor Necrosis Factor (TNF) Receptor Super Family (TNFRSF) are potentially excellent targets for modulation which result in specific anti-tumor immune responses. C...

Full description

Bibliographic Details
Main Authors: Jamie Frankish, Debayan Mukherjee, Erminia Romano, Katharina Billian-Frey, Matthias Schröder, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jamie Honeychurch, Tim Illidge, Jaromir Sykora
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
CD40
HERA-CD40L
TNFRSF
TRAF2
tumor micro environment (TME)
antigen presenting cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160116/full

Similar Items

Similar Items